Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China · Delayed Price · Currency is CNY 33.72
+1.23 (3.79%)
At close: Mar 6, 2026
SHA:688076 Revenue
In the year 2025, Jiangsu Sinopep-Allsino Biopharmaceutical had annual revenue of 1.94B CNY with 19.57% growth. Jiangsu Sinopep-Allsino Biopharmaceutical had revenue of 415.62M in the quarter ending December 31, 2025, with 11.56% growth.
Revenue
1.94B
Revenue Growth
+19.57%
P/S Ratio
5.49
Revenue / Employee
957.99K
Employees
2,247
Market Cap
10.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | 318.00M | 19.57% |
| Dec 31, 2024 | 1.62B | 591.25M | 57.21% |
| Dec 31, 2023 | 1.03B | 382.26M | 58.69% |
| Dec 31, 2022 | 651.29M | 7.42M | 1.15% |
| Dec 31, 2021 | 643.87M | 77.00M | 13.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.53B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Aurisco Pharmaceutical | 1.62B |
| Liaoning Chengda Biotechnology | 1.39B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 976.44M |
| Bio-Thera Solutions | 933.69M |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |